83410-16-6

Basic information

• Product Name: 4-CHLORO-5-IODO-2,6-DIMETHYLPYRIMIDINE
• Synonyms: 4-CHLORO-5-IODO-2,6-DIMETHYLPYRIMIDINE
• CAS NO: 83410-16-6
• Molecular Formula: C₆H₆ClIN₂
• Molecular Weight: 268.48
• Mol File: 83410-16-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 4-CHLORO-5-IODO-2,6-DIMETHYLPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-5-IODO-2,6-DIMETHYLPYRIMIDINE(83410-16-6)
• EPA Substance Registry System: 4-CHLORO-5-IODO-2,6-DIMETHYLPYRIMIDINE(83410-16-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 83410-16-6(Hazardous Substances Data)

Upstream product

• 83410-37-1 5-Iodo-2,6-dimethyl-4(3H)-pyrimidinone 
• 83410-37-1 5-iodo-2,6-dimethyl-pyrimidin-4-ol 
• 6622-92-0 4-hydroxy 2,6-dimethylpyrimidine 

Downstream Products

• 83410-49-5 4-chloro-2,6-dimethyl-5-styrylpyrimidine 
• 127588-24-3 4-chloro-2,6-dimethyl-5-phenylpyrimidine 
• 38202-09-4 2,4-dimethyl-5,6-diphenylpyrimidine 
• 83410-45-1 4-chloro-2,6-dimethyl-5-(phenylethynyl)pyrimidine 
• 159237-74-8 methyl(4-(4-bromobenzylamino)-2,6-dimethylpyrimidin-5-yl)ketone 
• 159237-77-1 4-(4-bromobenzylamino)-2,6-dimethyl-5-(1-ethoxyvinyl)pyrimidine 
• 1027898-62-9 1-(4-{[2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-2,6-dimethyl-pyrimidin-5-yl)-ethanone 
• 128266-84-2 2,4-dimethylpyrrolo<2,3-d>pyrimidine 
• 128266-77-3 4-azido-2,6-dimethyl-5-phenylpyrimidine 
• 83410-46-2 2,4-dimethyl-6-phenylthieno<2,3-d>pyrimidine 
• 83410-51-9 2,4-dimethyl-6-phenyl-7H-pyrrolo<2,3-d>pyrimidine 
• 83410-47-3 4-amino-2,6-dimethyl-5-phenylethynylpyrimidine 
• 83410-50-8 4-azido-2,6-dimethyl-5-styrylpyrimidine 
• 70542-19-7 2,4-dimethyl-5(E)-styrylpyrimidine 

Relevant articles and documents

Compounds for treating spinal muscular atrophy

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

Metabolites of the angiotensin II antagonist tasosartan: The importance of a second acidic group

Described in this paper is the synthesis and pharmacological activity of five metabolites of the angiotensin II antagonist tasosartan (1). Of particular interest is the effect of the additional acidic group of the enol metabolite (8) on activity. As suggested by the structural-activity relationship of other angiotensin II antagonist series, a second acidic group can improve receptor binding activity but decrease in vivo activity after oral dosing. The metabolic introduction of a second acidic group in tasosartan bypasses this problem and contributes to the excellent profile of the compound. A molecular modeling study provides a rationale for the role of the enol group of 8 in AT1 receptor binding.

Studies on pyrimidine derivatives. XXVIII. Synthesis of pyridopyrimidine derivatives by cross-coupling of halopyrimidines with olefins and acetylenes

-